SeaStar Medical Announces $4M Securities Offering

SeaStar Medical Holding ( (ICU) ) has provided an announcement.

On July 10, 2025, SeaStar Medical Holdings Corporation announced a securities purchase agreement with institutional investors, resulting in a registered direct offering and concurrent private placement of common stock and warrants, expected to close on July 11, 2025. The offering, priced at-the-market under Nasdaq rules, is anticipated to generate approximately $4 million in gross proceeds, which SeaStar Medical plans to use for general corporate purposes, including working capital and capital expenditures.

The most recent analyst rating on (ICU) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on SeaStar Medical Holding stock, see the ICU Stock Forecast page.

Spark’s Take on ICU Stock

According to Spark, TipRanks’ AI Analyst, ICU is a Underperform.

SeaStar Medical Holding faces significant financial challenges, with negative equity and reliance on external financing posing risks to its financial health. Technical indicators show bearish momentum, and valuation metrics highlight ongoing losses, contributing to a low overall stock score.

To see Spark’s full report on ICU stock, click here.

More about SeaStar Medical Holding

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Its first commercial product, QUELIMMUNE (SCD-PED), is FDA approved for treating acute kidney injury due to sepsis in critically ill pediatric patients. The company is also conducting trials for its Selective Cytopheretic Device (SCD) therapy in adult patients with acute kidney injury.

Average Trading Volume: 6,356,210

Technical Sentiment Signal: Sell

Current Market Cap: $9.55M

Find detailed analytics on ICU stock on TipRanks’ Stock Analysis page.